Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Optimize your pharmaceutical portfolio strategy

Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.

Drive commercial success

drive commerical success pharma intelligence

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
Country-specific treatment algorithms and reimbursement scenarios
Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Pharmapremia: Benchmark better and optimize your drug development pipeline

Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.

Key benefits:

Manage portfolio risks
Analyze success factors
Create meaningful benchmarks

In Vivo: strategic insights for life sciences decision-makers

In Vivo offers comprehensive coverage of the global medical industry’s competitive landscape.

Key benefits:

Cutting edge thought leadership
Expert analysis
Hear from news makers

In Vivo

World In Motion The Shape Of The New Health Care Technology Ecosystem In 2022

By Ashley Yeo 14 Jun 2018

The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.

Topic Business strategies Digital Health

View article
In Vivo

How The EHR And New Data Streams Are Influencing Clinical Practice

By Mark Ratner 14 Jun 2018

A plethora of clinical studies are showing that new types of data, often captured in the EHR, can help improve the correlation between treatments and outcomes and favorably affect patient care as well as enhance drug development.

View article
Datamonitor Healthcare

Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 1

By Jack Allen 08 Jun 2018

Zach McLellan and Jack Allen are joined by guest analysts Dominique Fontanilla and Hardik Patel. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

Topic Cancer

Full podcast
Datamonitor Healthcare

Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 2

By Jack Allen 08 Jun 2018

Zach McLellan and Jack Allen are joined by guest analyst Maria Berezina. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

Topic Cancer

Full podcast
Datamonitor Healthcare

Approval of Sun Pharmas Yonsa in Prostate Cancer Podcast

By Zachary McLellan 29 May 2018

Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of Sun Pharma's Yonsa in prostate cancer, and broad market commentary on Tesaro, Gilead, Clovis, Portola, BMS and Celgene

Topic Company analysis

Full podcast
Citeline, Scrip, Biomedtracker, Datamonitor Healthcare

ASCO Essentials Webinar 2018 Recording

By Mary Jo Laffler 29 May 2018

Just in time for your 2018 ASCO Annual Meeting planning, join analysts from Datamonitor Healthcare, Biomedtracker, Citeline, Scrip, and Pink Sheet for their expert opinions on what you need to know to get the most from the meeting. Let our experts present their top picks from the thousands of abstracts being presented at ASCO.

Topic Clinical trials

Full video
Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Topic Deal trends

Single report
Datamonitor Healthcare

Gene therapy

15 May 2018

Topic Cell and gene therapy

Full video
Datamonitor Healthcare

Dyslipidemia Market Overview Webinar How the Rise of Add-on Therapies will Spur Growth of the Dyslipidemia Market

By Jack Allen 15 May 2018

Jack Allen, Senior Analyst, Cardiovascular and Metabolic, Datamonitor Healtcare, leads the webinar. Topics covered: Overview of the Dyslipidemia Market Treatment Options Pipeline Therapies in Development Prescribing Trends Dyslipidemia Forecast.

Topic Dyslipidaemia

Full video
In Vivo

Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

By William Looney 15 May 2018

On October 5, In Vivo convened a group of top market-access specialists and industry and investment analysts to consider a central strategic challenge facing all innovators in biopharma: how to pay for the next wave of cures. Finding the answer first depends on a rebranding of the function itself – it’s not market access to products; it’s patient access to progress.

Topic Strategy

View article
Datamonitor Healthcare

Datamonitor Healthcare Podcast 16 February 2018

By Zachary McLellan 15 May 2018

Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including a recap of the 2018 BIO CEO conference, Phase IIb results of aramchol in HIV-lipodystrophy NAFLD or NASH patients, and the approval of Ereleada (apalutamide) in non-metastatic castration-resistant prostate cancer.

Topic Business strategies BioPharmaceutical

Full podcast
Datamonitor Healthcare

HIV Market Growth webinar

By Michael Haydock 15 May 2018

Mr. Haydock & Mr. Haas used the exclusive information within Datamonitor Healthcare and Biomedtracker to present a view of the market for HIV drugs. Informa Pharma Intelligence forecasts HIV sales revenues to increase in the US and five major EU markets to a peak of $22.7bn in 2024 before generic erosion triggers a market decline.

Full video
Datamonitor Healthcare

Datamonitor Healthcare Podcast 04 April 2018

By Jack Allen 15 May 2018

Zach McLellan & Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including analysis on Allogene's announcement that they are in-licensing the TALEN technology from Pfizer to commericalise and develop allogeneic, potentially leading to a strong acceleration of CART therapies.

Topic Drug development landscape

Full podcast
Datamonitor Healthcare

Podcast - Analyst Opinion on Approval of AndexXa for reversal of Eliquis and Xarelto

By Zachary McLellan 11 May 2018

Zach McLellan, Jack Allen, and guest analyst Cameron Findlater discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of AndexXa for reversal of Eliquis and Xarelto & Eli Lilly's acquisition of ARMO Biosciences.

Full podcast
In Vivo

Pharma Sourcing And Procurement: The New Strategy Of Spend

11 May 2018

Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise?In Vivotalks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value. (3) Work fast – spend forward. (4) Reach out earn the business.

Topic BioPharmaceutical

View article